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Hepcidin, the iron-regulatory hormone and acute
phase reactant, is proposed to contribute to the path-
ogenesis of atherosclerosis by promoting iron accu-
mulation inplaquemacrophages, leading to increased
oxidative stress and inflammation in the plaque (the
‘‘iron hypothesis’’). Hepcidin and iron may thus repre-
sent modifiable risk factors in atherosclerosis. We
measured hepcidin expression in Apoe/ mice with
varying diets and ages. To assess the role of macro-
phage iron in atherosclerosis, we generated Apoe/
mice with macrophage-specific iron accumulation
by introducing the ferroportin ffe mutation. Macro-
phage iron loadingwas also enhanced by intravenous
iron injection. Contrary to the iron hypothesis, we
found that hepatic hepcidin expression was not
increased at any stage of the atherosclerosis progres-
sion in Apoe/ or Apoe/ffemice and that the athero-
sclerotic plaque size was not increased in mice with
elevated macrophage iron. Our results strongly argue
against any significant role of macrophage iron in
atherosclerosis progression in mice.
INTRODUCTION
Whether iron promotes atherosclerosis is an unresolved ques-
tion.Multiple studies inanimals andhumansover the last 30 years
assessed the effect of increasedbody iron on atherosclerosis but
have yielded inconsistent results (Sullivan, 2007). Although iron is
present in humanatherosclerotic plaqueat higher concentrations
than in healthy arterial tissue (Stadler et al., 2004), it is not clear
why iron accumulates in the plaque, whether it is deleterious,
andwhether its specific cellular and subcellular location is impor-
tant for any harmful effects. The macrophage is a key cell type in
the formation and fate of atherosclerotic plaque, eventually
evolving into a foamcell that undergoes apoptosis. Iron catalyzes
the generation of reactive oxygen species and could therefore1436 Cell Reports 5, 1436–1442, December 12, 2013 ª2013 The Autpromote lipid oxidation and contribute to atherosclerotic plaque
instability (Ramakrishna et al., 2003). The liver-produced
hormone hepcidin is the main regulator of body iron levels and
its tissue distribution (Ganz and Nemeth, 2012). Hepcidin
controls the major flows of iron into plasma: the absorption of
dietary iron in the intestine, recycling of iron by macrophages
that ingest old erythrocytes and other cells, and mobilization of
stored iron from hepatocytes. Iron is exported from these tissues
into plasma through ferroportin, the sole cellular iron efflux chan-
nel and the hepcidin receptor. Hepcidin causes endocytosis and
degradation of ferroportin, leading to the retention of iron in cells
and decreased flow of iron into plasma. Hepcidin, as an acute
phase protein, is increased in inflammatory disorders, where it
causes iron sequestration in macrophages and hypoferremia
(Ganz and Nemeth, 2012). Considering the chronic inflammatory
nature of atherosclerotic disease, hepcidin production and
plasma concentrations would be expected to increase in athero-
sclerosis. In his refined ‘‘iron hypothesis,’’ Sullivan proposed that,
under the influence of the increased concentrations of hepcidin,
iron is primarily sequestered in macrophages and that iron-laden
macrophages within the plaque are an important promoter of
atherosclerosis (Sullivan, 2009b). Iron overload that spares
macrophages, as in human hereditary hemochromatosis caused
by hepcidin deficiency, is not associated with increased inci-
dence of cardiovascular diseases, including coronary artery
disease, other forms of ischemic heart disease, stroke, or periph-
eral artery disease, except for cardiomyopathy caused by iron-
mediated damage to cardiomyocytes (Sullivan, 2009a). Several
mouse models of iron overload (i.e., hereditary hemochromato-
sis) are available, but, like their human counterparts, they accu-
mulate iron in hepatocytes rather than macrophages and thus
are inappropriate for studies on the role of excess macrophage
iron in atherosclerotic plaques. The flatiron (ffe) mouse is the first
mouse model that accumulates iron in macrophages without
other confounding abnormalities (Zohn et al., 2007). The flatiron
mouse has a heterozygous H32R mutation in ferroportin that
causes a dominant negative mistrafficking of the iron exporter.
The relative deficiency of ferroportin results in iron overload in
macrophages and replicates the effect of increased hepcidin
concentration on macrophages. We generated a mouse modelhors
Figure 1. Saa3 mRNA, Hepcidin mRNA, and
Liver Iron Analysis in Atherosclerotic Mice
(A and B) Wild-type, Apoe/, ffe, and Apoe/ffe
mice were fed for 4 months with either a standard
chow (300 ppm Fe, gray bars) or the high-fat diet
(300 ppm Fe, black bars). (A) Serum amyloid A-3
(Saa3) and (B) hepcidin (Hamp) mRNA levels were
measured by qPCR. Values shown are means of
DCt (i.e., Ct Rpl4  Ct Hamp or Saa3) ± SD.
(C) Liver nonheme iron content (mean ± SD). For
each gender and diet, statistical analysis was
conducted to evaluate the effect of atherosclerotic
genotype: Apoe/ mice were compared to WT,
andApoe/ffewere compared to ffemice. *p < 0.05,
**p < 0.01, and ***p < 0.001 by Student’s t test (n =
5–11). None of the comparisons in (B) are statisti-
cally significant.by breeding ffe with Apoe/ mice, a classical mouse model
of atherosclerosis, to study Apoe//ffe mutants that were
expected to have more macrophage iron than Apoe/ mice.
We examined the effect of increasedmacrophage iron on athero-
sclerosis progression and vascular calcification and also
explored the effect of atherosclerosis or high-fat diet on systemic
(hepatic) hepcidin production.
RESULTS
The Effects of Atherosclerosis and Dietary Fat on
Hepcidin
Inflammation and Hepcidin
To test whether the liver hepcidin production was increased
by the atherosclerosis-associated systemic inflammation, weCell Reports 5, 1436–1442, Decompared Apoe/ to wild-type (WT)
mice and Apoe/ffe to ffe mice after
4 months of either the low-fat or high-
fat diet, both containing 300 ppm iron.
The acute-phase protein serum amyloid
A-3 was used as a sensitive biomarker
of inflammation. On the high-fat diet,
Apoe/ mice compared to WT mice
and Apoe/ffe mice compared to ffe
mice had significantly increased Saa3
mRNA (2- to 4-fold) in both genders,
consistent with the severe atheroscle-
rosis seen in mice lacking ApoE (see
Figure 1A). As expected on the low-
fat diet causing much milder atheroscle-
rosis, the increase in Saa3 was absent
or less consistent in Apoe/ or Apoe/ffe
mice.
HampmRNA levels were not increased
but were consistently similar in Apoe/
mice compared to WT mice or in Apoe/
ffe mice compared to ffe mice on the
same diet (Figure 1B).
To determine whether a more marked
inflammatory effect of atherosclerosison hepcidin emerged with age, groups of Apoe/ and Apoe/
ffe mice were maintained on the high-fat diet containing 300
ppm Fe for 8 months, but no further increase in Saa3 was
observed compared to the 4-month time point (Figure S1A), indi-
cating that inflammation was already maximal after 4 months of
the high-fat diet. Hepcidin mRNA in the 8-month group
compared to that in the 4-month group was not increased but
rather diminished in females or remained the same in males
(Figure S1B).
In addition to Saa3, we also examined hepatic interleukin-6
(Il6) and haptoglobinmRNA expression. Il6 expression was close
to the lower limit of detection, and for either marker, only a small
and inconsistent increase was detected in atherosclerotic mice
compared to nonatherosclerotic mice (Figure S2), suggesting
that the systemic inflammation accompanying atherosclerosiscember 12, 2013 ª2013 The Authors 1437
Figure 2. Saa3mRNA, Hepcidin mRNA, and
Liver Iron Analysis in Apoe/ Mice
(A and B) For 2 months, Apoe/ mice were fed
either the low-fat diet containing 50 ppm Fe (LFD,
gray bars) or the high-fat diet containing 50 ppmFe
(HFD, black bars) (n = 6–10). F, females; M, males.
(A) Saa3 mRNA. (B) Hepcidin mRNA.
(C) Liver nonheme iron concentrations. Vertical
bars show the means, and error bars show SDs.
Statistical analysis was performed to evaluate the
effect of worsening atherosclerosis: mice on the
low-fat diet were compared to those on the high-
fat diet by Student’s t test. ***p% 0.001. **p = 0.01.in these mouse models is relatively mild and possibly insufficient
to promote hepcidin production.
Iron Stores and Hepcidin
A high-fat diet could interfere with iron absorption (Sonnweber
et al., 2012; Chung et al., 2011), thereby decreasing liver iron
stores and counterregulating the effect of inflammation on hep-
cidin. However, at 4 months, except for the difference between
ffe and Apoe/ffemice on the low-fat diet, there was no difference
in liver iron content between WT and Apoe/ mice when main-
tained on the same diet (either low fat or high fat, both with 300
ppm iron) or between ffe and Apoe/ffe littermates on the high-fat
diet (Figure 1C). On the whole, this indicates that the lack of
hepcidin increase in atherosclerotic mice cannot be explained
by the counterregulation of hepcidin by liver iron stores. At
8 months, liver iron stores of Apoe/ and Apoe/ffe mice were
higher than at 4 months as would be expected (Figure S1C),
but despite this, hepcidin mRNA did not increase (Figure S1B).
The inhibitory effect of the high-fat diet on iron stores within
each genotype was either small (female WT and Apoe/) or
absent (male WT and Apoe/ and both genders of Apoe/ffe)
(Figure 1C). Only ffemice showed reproducible decrease in liver
iron on the high-fat diet in both genders, suggesting that the
high-fat diet may manifest its inhibitory effect under conditions
where iron absorption is already stressed, as may be the case
in ffemice where the decreased expression of mutant ferroportin
in the intestinal epithelium could limit absorptive capacity for
iron. It is interesting that, even on the low-fat diet, Apoe/ffe
mice had significantly less liver iron than ffe mice (Figure 1C),
showing that Apoe ablation itself can inhibit iron absorption,
possibly through its effects on lipid metabolism.
Because hepcidin expression is increased by iron loading
(Ganz and Nemeth, 2012), we considered that feeding mice
with 300 ppm iron for 4 months may have raised baseline hepci-
din mRNA enough to render it poorly responsive to inflamma-
tion. We therefore examined Apoe/ mice fed diets containing
50 ppm iron (close to the mouse daily iron requirement), with
either low or high fat content for 2 months. Saa3 mRNA
increased on the high-fat diet compared to the low-fat diet (Fig-
ure 2A). However, hepatic Hamp mRNA expression was not
induced but even decreased (2-fold) in Apoe/ mice fed the
high-fat diet (Figure 2B). The mild hepcidin decrease could
potentially be related to iron malabsorption on the high-fat diet
(Sonnweber et al., 2012; Chung et al., 2011), although only
female Apoe/ mice had a small decrease in liver iron content
(Figure 2C).1438 Cell Reports 5, 1436–1442, December 12, 2013 ª2013 The AutTogether, the lack of hepcidin increase in atherosclerotic mice
on either 50 ppm or 300 ppm iron diets, with or without the ffe
mutation, reflects the very low intensity of the inflammatory
response associated with the atherosclerotic process, insuffi-
cient to raise hepcidin significantly.
The Effects of Macrophage Iron on Atherosclerosis
The Effects of the Ferroportin ffe Mutation
To explore the effects of iron retention in macrophages on
atherosclerosis, we compared Apoe/ffe mice with Apoe/
mice. After 4 months on the high-fat diet, Apoe/ffe mice had
more splenic iron than Apoe/ mice (Figure 3A), confirming
that the ffe mutation caused macrophage iron retention. Perls’
stains of spleen sections confirmed that iron retention was
confined to the macrophage-rich red pulp (Figure S3).
Contrary to our hypothesis, the size of atherosclerotic lesions
in Apoe/ffe mice was not larger, but even smaller, than in
Apoe/ mice (Figure 3B). Furthermore, en face analysis of
whole aortas, innominate artery lesions, and chondrocytes count
revealed no significant effects of ffe in the Apoe/ model (data
not shown). However, aortic lesion calcification was modestly
higher in Apoe/ffe mice than in Apoe/ mice, although this did
not reach statistical significance for individual genders (Fig-
ure 3C). Furthermore, the effect of iron on calcification was not
consistently observed as described in the next paragraph for
mice treated with parenteral iron.
To ascertain whether the ffe mutation promotes atheroscle-
rosis in the absence of the atherogenic Apoe mutation, we
compared ffe mice to WT mice after 4 months on the high-fat
diet. Atherosclerotic lesions were very small in both groups
(median lesions sizes were 219 mm2 in WT, n = 13; and
144 mm2 in ffe mice, n = 26), and neither WT nor ffe mice devel-
oped calcifications.
The Effects of Parenteral Iron Supplementation
To further enhance macrophage iron loading in atherosclerotic
mice, we administered parenteral iron by weekly injections of
2 mg iron sucrose for 8 weeks while feeding mice the high-fat
diet (50 ppm iron). Treatment with iron sucrose resulted in
greater iron accumulation not only in the liver and the spleen
(Figures 4A and 4B; Figure S4) but also around the aortic lesions
(Figure 4D, tissue sections of Apoe/ mice are shown, and
similar iron accumulation was observed in Apoe/ffe). Hepatic
hepcidin expression was also increased by iron sucrose treat-
ment (Figure 4C). However, the size of atherosclerotic lesions
did not increase, but even tended to decrease with ironhors
Figure 3. Despite Iron-Loaded Macrophages, Apoe/ffe Mice Do Not Develop More Severe Atherosclerosis than Apoe/ Mice
(A and B) Apoe/ (n = 15) and Apoe/ffe (n = 19) mice were fed the high-fat diet with 300 ppm Fe for 4 months. (A) Nonheme spleen iron content was measured to
confirm macrophage iron loading associated with ffe mutation. Means and SDs are shown. (B) Atherosclerotic lesion size is given in squared micrometers
(horizontal lines represent the means).
(C) Calcification count (mean percentage of slides showing calcification ± SD). For each gender,Apoe/mice were compared toApoe/ffemice using Student’s t
test (*p < 0.05; **p < 0.01; ***p < 0.001).treatment, in bothApoe/ andApoe/ffemice (Figure 4E), and no
lesion calcifications were observed. There was also no differ-
ence in lesion size when Apoe/ mice were compared to
Apoe/ffe mice on the same treatment. Hepatic Il6 and Saa3
mRNA levels were unchanged by parenteral iron supplementa-
tion (Figure S5).
DISCUSSION
We report that liver hepcidin, the central regulator of iron ho-
meostasis, is not influenced by inflammation in a standard
mousemodel of atherosclerosis (Apoe/) after 2, 4, or 8 months
on the high-fat diet. The results argue against the hypothesis that
increased systemic hepcidin promotes macrophage iron reten-
tion in atherosclerosis. Furthermore, we report that increased
macrophage iron, achieved either through a genetic mutation
in the iron exporter ferroportin or through parenteral iron admin-
istration, also fails to promote atherosclerosis in mice. Although
increased cellular iron would be expected to result in greater
oxidative stress, one possible explanation for the lack of effect
of macrophage iron loading on atherosclerosis is that iron is
effectively chaperoned in macrophages by ferritin, and macro-
phage antioxidant defenses are very efficient. Compared to
parenchymal cells such as hepatocytes and cardiac myocytes,
macrophages are highly resistant to iron-induced damage, as
evidenced by the lack of clinical consequences of the pure
loss-of-function mutations in ferroportin (classical ferroportin
disease) (Le Lan et al., 2011).
By measuring liver iron content, we demonstrated that the
absence of systemic (hepatic) hepcidin increase in athero-
sclerotic mice was not due to inhibitory effects of the high-fat
diet on iron absorption (Sonnweber et al., 2012). The absence
of hepcidin increase was also not due to anemia, as a subset
of ffe, Apoe/, and Apoe/ffe mice in which a sufficient sample
was available for hemoglobin measurements, all had normal
hemoglobin (data not shown). Instead, the absence of hepcidin
increasemay be related to the relatively mild systemic inflamma-
tion caused by atherosclerosis in our model and in most human
atherosclerosis. Although hepatic Saa3 mRNA was elevated inCell Reour model, other markers of inflammation, including hepatic Il6
and haptoglobin mRNA, were not consistently increased. In
humans, measurements of serum IL-6, the most important
inflammatory driver of hepcidin (Ganz and Nemeth, 2012),
show statistically significant differences when thousands of
patients are studied but also a very large overlap between
atherosclerotic heart disease cases and controls [Reykjavik
study, loge(IL-6) = 0.78 ± 0.74 versus 0.65 ± 0.76; British
Regional Heart Study, 0.97 ± 0.62 versus 0.79 ± 0.63) (Danesh
et al., 2008). Thus, the mild inflammation in the mouse models
used in our study is not out of line with human disease character-
istics. Although plaque inflammation is central to the athero-
sclerotic process, systemic inflammation is not an invariant
feature of atherosclerosis. It requires very sensitive markers,
such as high sensitivity C-reactive protein in humans or Saa3
in mice, to be reliably detectable.
Our study cannot exclude the possibility that hepcidin is
locally increased in macrophages and adipocytes in the plaque
environment and may promote macrophage iron accumulation
locally. However, because the manipulations of macrophage
iron content in our model (designed to mimic the effect of either
systemic or local hepcidin excess) failed to alter the atheroscle-
rotic phenotype, there was no compelling rationale to study the
local production of hepcidin in the plaque.
In addition to introducing ffe ferroportin mutation on to an
Apoe/ background, we enhanced macrophage iron loading
by injecting Apoe/ and Apoe/ffe mice on the Western diet
with iron sucrose, a common adjunctive therapy used in patients
with chronic kidney diseases, also predisposed to accelerated
atherosclerosis (Johnson et al., 2010). Iron sucrose injections
load macrophages effectively because the compound is first
processed by macrophages in order to release iron from the
carrier. To balance out the losses, mice normally require about
35 mg of iron per gram of diet and consume about 4 g of food
per day (although not all of the dietary iron is absorbed), thus
acquiring less than 1 mg of iron per week. We injected 16 mg
of iron over 2 months. Nevertheless, despite nonphysiologically
high concentrations of macrophage iron, we did not observe any
worsening of the atherosclerotic phenotype, as the lesionsports 5, 1436–1442, December 12, 2013 ª2013 The Authors 1439
Figure 4. Parenteral Iron Administration
Does Not Worsen Atherosclerosis in
Apoe/ and Apoe/ffe Mice
(A and B) Apoe/ and Apoe/ffemice were fed the
high-fat diet for 2 months (50 ppm Fe). One group
received weekly iron sucrose injections for
8 weeks (16 mg iron total, HFD+Fe) (n = 13 for
Apoe/ and 9 for Apoe/ffe), and the other group
did not (HFD) (n = 13 for Apoe/ and 7 for Apoe/
ffe). (A) Nonheme liver iron and (B) spleen iron
content were quantitated to confirm macrophage
iron loading induced by iron sucrose injections.
(C) Hepatic Hamp mRNA expression. For (A), (B),
and (C), means and SDs are shown.
(D) Histological examination of iron loading in
the aortic lesions. Tissue iron was detected by
enhanced Perls’ stain (green). Scale bars, 100 mm.
Illustrative tissue sections from Apoe/ mice are
shown; Apoe/ffe animals had an equivalent iron
loading pattern.
(E) Atherosclerotic lesion size is given in squared
micrometers (horizontal lines represent the
means). For each genotype (either Apoe/ or
Apoe/ffe), statistical analysis was performed to
evaluate the effect of iron sucrose injections.
Furthermore, for each condition (either HFD or
HFD+Fe), Apoe/ mice were compared to Apoe/
ffemice. **p = 0.01 and ***p% 0.001, by Student’s
t test. No statistically significant difference be-
tween the groups was observed in (E).tended to be smaller than in untreatedmice, in both Apoe/ and
Apoe/ffe genotypes.
Our study did not specifically test whether depletion of
macrophage iron, such as in frank iron deficiency or with
hepcidin lowering agents, would be protective. Recently, Saeed
and colleagues reported that pharmacological suppression of
hepcidin synthesis through inhibition of the bone morphogenetic
protein (BMP) pathway decreased atherosclerosis in a model
similar to ours (Saeed et al., 2012). However, inhibitors of BMP
signaling would be expected to have profound effects on
many other biological processes potentially involved in the
formation of the atherosclerotic plaque (Cai et al., 2012). Indeed,
inhibition of BMP signaling inmice by overexpression of the BMP
inhibitor MGP (Matrix gla protein) reduced atherosclerotic lesion
size, intimal and medial calcification, and inflammation (Yao
et al., 2010). Saeed et al. did not demonstrate whether replace-
ment of hepcidin reverses the effect of the BMP inhibitor on
atherosclerotic plaque size. Rather, they evaluated ex vivo
foam cell formation and cholesterol efflux aftermicewere treated
in vivo with the BMP inhibitor with or without a 2-day hepcidin
injection. In these specific conditions, hepcidin addition to the
BMP inhibitor increased foam cell formation and decreased
cholesterol efflux compared to the BMP inhibitor by itself. A
hepcidin-only condition was not tested. Further work using
hepcidin-specific antagonists is required to examine whether
pharmacological hepcidin suppression by itself affects progres-
sion of atherosclerosis.
Other studies that analyzed the effect of an iron-deficient diet
on atherosclerosis progression did not observe a consistent
result: an iron-deficient diet (11 ppm compared to 85 ppm iron)
modestly reduced atherosclerotic lesions in Apoe/ mice1440 Cell Reports 5, 1436–1442, December 12, 2013 ª2013 The Autafter 3 months (Lee et al., 1999), but not after 5 months (Lee
et al., 2003). A different model of reducing iron load using iron
chelation in Apoe/ mice (daily injections of desferrioxamine
for 10 weeks) modestly decreased the atherosclerotic lesion
size (Zhang et al., 2010), but so did dietary iron loading using
20,000 ppm iron diet for 6, 12, or 24 weeks (Kirk et al., 2001).
Although dietary iron loading causes preferential iron accumula-
tion in hepatocytes rather than macrophages, in this study, both
liver iron and spleen iron increased (10-fold and 3-fold,
respectively). All of the aforementioned studies used Apoe/
mice of the same background strain as our study. We surmise
that any effect of macrophage iron on atherosclerosis is so
small that contradictory conclusions may be reached perhaps
because of differences in study design. Taken together with
our results, the inconsistent effects of iron in atherosclerotic
mouse models do not support the hypothesis that iron is
an important aggravating factor in the pathogenesis of
atherosclerosis.EXPERIMENTAL PROCEDURES
Animals and Diets
Experiments were conducted in accordance with guidelines by the National
Research Council and were approved by the University of California, Los
Angeles. Apoe/ mice on a C57BL/6J background and WT C57BL/6J mice
were purchased from The Jackson Laboratory. ffeH32R/+ mice (Zohn et al.,
2007) were obtained from Dr. Jerry Kaplan, University of Utah. As ffe mice
were on a C3H/HeJ background, we used marker-assisted accelerated
backcrossing to transfer the ffe mutation (chromosome 1) on to a C57BL/6
background to match the background of Apoe/ mice. After backcrossing,
ffeH32R/+ mice were mated with Apoe/ mice to generate Apoe+/ ffeH32R/+
mice, and subsequent breeding of these mice to Apoe/ mice generatedhors
Apoe/ ffeH32R/+ (referred to as Apoe/ffe for simplicity), as well as Apoe/
littermate controls. Similarly, ffeH32R/+ mice and WT littermate controls
were generated from crossing ffeH32R/+ to each other. Because of known
gender differences in iron status (Courselaud et al., 2004), where females
have higher iron stores and hepcidin expression than males, the two genders
were analyzed separately. Gender-related differences in atherosclerosis
severity in mice may also exist, with females exhibiting larger lesion sizes in
many studies, although this remains controversial (Meyrelles et al., 2011).
All mice were initially maintained on standard chow (Diet 8604, Harlan
Teklad). For atherosclerotic plaque assessment, we placed 6-week-old
Apoe/ and Apoe/ffe littermates on the Western diet (Research Diets, diet
no. D12079B, 21% fat [WT/WT], 0.21% cholesterol [WT/WT]), which was
custom made to contain 300 ppm iron (equivalent to the iron content of
standard chow). Another set of Apoe/ and Apoe/ffe mice were compared
after 2 months on the classic Western diet (50 ppm iron) with or without weekly
injections of 2 mg iron sucrose (Venofer, Vifor [International]) to enhance
macrophage iron loading (eight injections total, equaling 16mg of iron). Plaque
size was also examined inWT and ffe littermates that were fed the high-fat diet
(300 ppm iron) for 4 months.
For hepcidin assessment, the following groups of mice were used (all placed
on specific diets at the age of 6 weeks): WT and ffeH32R/+ littermates, and
Apoe/ and Apoe/ffe littermates, all fed for 4 months either standard chow
(300 ppm iron) or the Western diet with 300 ppm iron. A set of Apoe/ and
Apoe/ffe littermates were also compared after 8 months on the Western diet
containing 300 ppm iron. A set of Apoe/ mice were fed for 2 months the
classic Western diet (50 ppm iron) or the low-fat version of the diet (50 ppm
iron).
For all mice, liver and spleen were harvested and divided into flash-frozen
samples in liquid nitrogen for RNA and iron measurement and in 10% formalin
for paraffin embedding.
Lesion Quantification
The mice were euthanized, and hearts were perfused with 10% buffered
formalin via the left ventricle for 4 min. The heart and proximal aorta were
excised, and the apex and lower half of the ventricles were removed. The
remaining specimen was embedded in O.C.T. Compound (Tissue-Tek, Fisher
Scientific), frozen on dry ice, and stored at 80C until sectioning. Serial
cryosections were prepared through the ventricle until the aortic valves
appeared. From then on, every fifth 10-mm section was collected on slides
coated with poly-D-lysine until the aortic sinus was completely sectioned.
Sections were stained with hematoxylin and Oil Red O, which specifically
stains lipids. Slides were examined by light microscopy, and the atheroscle-
rotic lesion area was quantified with computer-assisted image analysis
(Image-Pro Plus, Media Cybernetics) as described elsewhere and averaged
over 40 sections (Qiao et al., 1994; Wang et al., 2004).
En Face Analysis of Aortas
The aorta, including the ascending arch, thoracic, and abdominal segments,
was dissected, gently cleaned of the adventitia, and stained with Sudan IV
5. The surface lesion area was quantified with computer-assisted image anal-
ysis (Image-Pro Plus, Media Cybernetics) as previously described (Qiao et al.,
1994; Wang et al., 2004).
Calcification Quantification
Sections of the aortic roots were stained with hematoxylin and examined by
light microscopy. Forty sections per mouse were examined, and the sections
with visible calcification were counted (Qiao et al., 1994). Results are ex-
pressed as a percentage of slides with visible calcifications.
Measurement of Iron Parameters
Spleen and liver nonheme iron concentrations were determined as described
elsewhere (Ramos et al., 2012), using acid treatment followed by a colorimetric
assay for iron quantitation (Sekisui Diagnostics). Deparaffinized sections
were stained with Perls’ Prussian blue stain for nonheme iron enhanced with
the SG peroxidase substrate kit (Vector Labs) and counterstained with nuclear
fast red.Cell ReQuantitation of mRNA Levels
Total RNA from mouse liver was extracted using Trizol (Invitrogen). cDNA was
synthesized using iScript (Biorad). Quantitative PCR (qPCR) reactions were
prepared with iQ SYBR Green Supermix (Biorad), and primers were indicated
in Table S1 and run in duplicate on a MyiQ Instrument (Biorad). Hamp, Saa3,
Il6, and haptoglobin mRNA expression were normalized by the reference
gene Rpl4 or Hprt. Results are expressed as DCt ± SD (i.e., the cycle threshold
differences between reference and target genes within each group of mice).
Statistical Analysis
The statistical significance of differences between groupswas evaluated using
Sigmaplot 11.0 package (Systat Software). The Student’s t test was used to
compare two groups of normally distributed data. The Mann-Whitney rank-
sum test was used to compare data that were not normally distributed. A
p value < 0.05 was considered as statistically significant. Data are represented
as mean value ± SD.
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